(Q35609713)

9 August 2017

1 reference

title

Cancer metastasis therapeutic targets and drug discovery: emerging small-molecule protein kinase inhibitors (English)

1 reference

9 August 2017

1 reference

1 reference

Tomi K Sawyer

1

1 reference

PubMed ID

14680449

9 August 2017

language of work or name

English

0 references

publication date

1 January 2004

1 reference

Expert Opinion on Investigational Drugs

9 August 2017

1 reference

9 August 2017

13

1 reference

9 August 2017

1

1 reference

9 August 2017

1-19

1 reference

Axis of evil: molecular mechanisms of cancer metastasis

9 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Genetic and epigenetic alterations as hallmarks of the intricate road to cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Overview of the clinical efficacy of investigational anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Dissemination and growth of cancer cells in metastatic sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Metastasis suppression: the evolving role of metastasis suppressor genes for regulating cancer cell growth at the secondary site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Critical determinants of cancer metastasis: rationale for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Metastasis to bone: causes, consequences and therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Orthotopic metastatic mouse models for anticancer drug discovery and evaluation: a bridge to the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Clinical targets for anti-metastasis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Cellular functions regulated by Src family kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Effects of the disintegrin eristostatin on individual steps of hematogenous metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Expression of nm23-H1 and nm23-H2 proteins in prostate carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

KiSS-1, a novel human malignant melanoma metastasis-suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Liver colonization competence governs colon cancer metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Modelling the molecular circuitry of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Current targets for anticancer drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

New roles for Src kinases in control of cell survival and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Genetic evidence for a role for Src family kinases in TNF family receptor signaling and cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

A causal role for E-cadherin in the transition from adenoma to carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Transcription factors as targets for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Genomic analysis of metastasis reveals an essential role for RhoC

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Involvement of c-Src in carcinoma cell motility and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Src kinase contributes to the metastatic spread of carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Role of integrins in cell invasion and migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Integrin activation controls metastasis in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Ras and Rho regulation of the cell cycle and oncogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

A Ras by any other name

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The ras signaling pathway in mammary tumorigenesis and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

RHO-GTPases and cancer

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Clinical, cellular, and molecular aspects of cancer invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Protein kinase activity associated with the avian sarcoma virus src gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Protein kinases--the major drug targets of the twenty-first century?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Receptor tyrosine kinases: the main targets for new anticancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Receptor tyrosine kinases as target for anti-cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Protein kinases as targets for anticancer agents: from inhibitors to useful drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

SRC homology-2 inhibitors: peptidomimetic and nonpeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Focal adhesion kinase as a potential target in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Adhesion-linked kinases in cancer; emphasis on src, focal adhesion kinase and PI 3-kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Src inhibitors: genomics to therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Targeting protein kinases for bone disease: discovery and development of Src inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Potentiation of epidermal growth factor receptor-mediated oncogenesis by c-Src: implications for the etiology of multiple human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Activation of c-Src by receptor tyrosine kinases in human colon cancer cells with high metastatic potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Activating SRC mutation in a subset of advanced human colon cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

A siren song from tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

CDKs and CKIs: molecular targets for tissue remodelling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Cyclin-dependent kinases: engines, clocks, and microprocessors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

A cell cycle regulator potentially involved in genesis of many tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Targeting serine/threonine protein kinase B/Akt and cell-cycle checkpoint kinases for treating cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Integrin-linked kinase, a promising cancer therapeutic target: biochemical and biological properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The rapamycin-sensitive signal transduction pathway as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

New insights into the interaction of Ras with the plasma membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Cell cycle targets of Ras/Raf signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Rationale for Ras and raf-kinase as a target for cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Role of angiogenesis in tumor growth and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Matrix metalloproteinases in tumor invasion: role for cell migration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Complex roles of tissue inhibitors of metalloproteinases in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

Inhibitors of integrins

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Parathyroid hormone related peptide and receptor expression in paired primary prostate cancer and bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Expression of the receptor for parathyroid hormone-related protein in normal and malignant breast tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Role of endothelin-1 in osteoblastic bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Bisphosphonates: their evolving role in the management of prostate cancer-related bone disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Improving the efficacy of antibody-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Trastuzumab: hopes and realities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Antisense therapy in oncology: new hope for an old idea?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Antisense anticancer oligonucleotide therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Cancer gene therapy: fringe or cutting edge?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Therapeutic cancer targeting peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

New tools for functional mammalian cancer genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Issues and progress with protein kinase inhibitors for cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Therapeutics targeting signal transduction for patients with colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Bone metastases in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Farnesyl transferase inhibitors as anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Inhibitors of protein farnesyltransferase as novel anticancer agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Development of anticancer drugs targeting the MAP kinase pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

New functions for the matrix metalloproteinases in cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

In vitro and in vivo antitumor effects of bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Nitrogen containing bisphosphonates induce apoptosis and inhibit the mevalonate pathway, impairing Ras membrane localization in prostate cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

New insights into the actions of bisphosphonate zoledronic acid in breast cancer cells by dual RhoA-dependent and -independent effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Surprise phase III failure for ZD1839.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Src family kinases in tumor progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Bone-targeted 2,6,9-trisubstituted purines: novel inhibitors of Src tyrosine kinase for the treatment of bone diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Bone-targeted Src kinase inhibitors: novel pyrrolo- and pyrazolopyrimidine analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Bone-targeted pyrido[2,3-d]pyrimidin-7-ones: potent inhibitors of Src tyrosine kinase as novel antiresorptive agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Src family kinases and HER2 interactions in human breast cancer cell growth and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

The Src-selective kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

4-anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.13.1.1

21 January 2018

Identifiers

DOI

10.1517/13543784.13.1.1

1 reference

9 August 2017

1 reference

PubMed ID

14680449